Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.59 |
| ▸ | CA1 | P00915 | 7/20 | 0.59 |
| ▸ | CA12 | O43570 | 8/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631093 | 1.00 | CA2 (0.59) | CA2CA1CA12CA9CA14 | |
| SCHEMBL12052154 | 1.00 | CA2 (0.59) | CA2CA1CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL31365115 | 0.98 | CA2 (0.57) | CA2CA1CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL7142051 | 0.98 | CA2 (0.57) | CA2CA1CA12CA9CA14 | |
| SCHEMBL84614 | 0.86 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL30358121 | 0.85 | ALDH1A1 (0.45) | CA2CA1 | |
| SCHEMBL3465330 | 0.85 | ALDH1A1 (0.45) | CA2CA1 | |
| SCHEMBL17061124 | 0.85 | ALDH1A1 (0.45) | CA2CA1 | |
| SCHEMBL30117178 | 0.85 | ALDH1A1 (0.45) | CA2CA1 | |
| SCHEMBL26101860 | 0.85 | ALDH1A1 (0.45) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| WO-2020114947-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | CA2 1107/4885CA1 3219/4885CA12 2671/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | CA2 3104/4885CA1 4685/4885CA12 4325/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | CA2 1107/4885CA1 3219/4885CA12 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.